EC grants orphan drug status to Biodexa’s oral FAP treatment
The European Commission (EC) has granted orphan drug designation to Biodexa Pharmaceuticals’ oral tablet formulation of rapamycin, eRapa.
The European Commission (EC) has granted orphan drug designation to Biodexa Pharmaceuticals’ oral tablet formulation of rapamycin, eRapa.
What's Your Reaction?
